



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: editorialoffice@wjgnet.com

http://www.wjgnet.com

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 10822

Title: Cost-effectiveness analysis of adjuvant therapy XELOX and FOLFOX4 for colon cancer based on MOSIAC and NO16968 trials

Reviewer code: 00535896

Science editor: Yuan Qi

Date sent for review: 2014-04-22 20:01

Date reviewed: 2014-05-24 20:57

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

1.) The INTRODUCTION part is too long and could be more precise. E.g. which protocol is the standard in an adjuvant therapy of colon, and only colon, not colorectal cancer. 2.) The presentation of literature in the text is inadequate. The presentation of literature should correspond to the guidelines of the journal and if said in the text e.g.: after lung and breast cancer(Siegel et al., 2013)..... Better: according to Siegel et al. [1]..... 3.) It will be also of benefit not to mention the Duke's Classification any more, therefore the UICC or AJCC- classification. 4.) In the INTRODUCTION part it is said that: "... adjuvant FOLFOX is a cost-effective treatment for stage II or III colon cancer compared..." adjuvant therapy is indicated in stage III (UICC/ AJCC) colon cancer. The basis of data for the treatment of stage II (UICC/ AJCC) is poor.